$RSLS
ReShape Lifesciences Inc. Stock $rsls

$rsls Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000162828017005305 Filed on May 10, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$1.963M	$1.472M	$1.069M
YoY Change	151.99%	37.7%	17.34%
Cost Of Revenue	$990.0K	$823.0K	$622.0K
YoY Change	47.32%	32.32%
Gross Profit	$973.0K	$649.0K	$447.0K
YoY Change	809.35%	45.19%	35.05%
Gross Profit Margin	49.57%	44.09%	41.81%
Selling, General & Admin	$5.853M	$5.940M	$1.379M
YoY Change	266.73%	330.75%	-70.85%
% of Gross Profit	601.54%	915.25%	308.5%
Research & Development	$2.760M	$2.400M	$2.512M
YoY Change	6.73%	-4.46%	12.14%
% of Gross Profit	283.66%	369.8%	561.97%
Depreciation & Amortization	$40.00K	$30.00K	$40.00K
YoY Change	0.0%	-25.0%	-20.0%
% of Gross Profit	4.11%	4.62%	8.95%
Operating Expenses	$8.613M	$8.340M	$3.891M
YoY Change	105.95%	114.34%	-44.09%
Operating Profit	-$7.640M	-$7.691M	-$3.444M
YoY Change	87.48%	123.32%	70.5%
Interest Expense	-$35.00K	-$54.00K	-$147.0K
YoY Change	-75.52%	-63.27%	-30.0%
% of Operating Profit
Other Income/Expense, Net	-$55.00K	$0.00	-$13.00K
YoY Change	511.11%	-100.0%
Pretax Income	-$6.840M	-$7.370M	-$7.410M
YoY Change	36.8%	-0.54%	3.35%
Income Tax
% Of Pretax Income
Net Earnings	-$7.730M	-$7.745M	-$3.581M
YoY Change	87.12%	116.28%	67.89%
Net Earnings / Revenue	-393.79%	-526.15%	-334.99%
Basic Earnings Per Share
Diluted Earnings Per Share	-$229.9B	-$320.9B	-$16670B
COMMON SHARES
Basic Shares Outstanding	16.79M shares	16.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.20M	$18.68M	$11.15M
YoY Change	-2.78%	67.53%	-2.45%
Cash & Equivalents	$5.827M	$41.71M	$2.123M
Short-Term Investments	$54.90M	$25.00M
Other Short-Term Assets	$705.0K	$1.004M	$870.0K
YoY Change	53.26%	15.4%	89.13%
Inventory	$747.0K	$928.0K	$1.870M
Prepaid Expenses	$433.0K	$805.0K
Receivables	$1.757M	$1.035M	$60.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$63.93M	$69.69M	$13.95M
YoY Change	352.79%	399.55%	7.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.044M	$903.0K	$300.0K
YoY Change	301.54%	201.0%	-33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$730.0K	$680.0K	$610.0K
YoY Change	19.67%	11.48%	-29.89%
Total Long-Term Assets	$1.044M	$903.0K	$910.0K
YoY Change	20.0%	-0.77%	-31.06%
TOTAL ASSETS
Total Short-Term Assets	$63.93M	$69.69M	$13.95M
Total Long-Term Assets	$1.044M	$903.0K	$910.0K
Total Assets	$64.98M	$70.59M	$14.86M
YoY Change	333.48%	375.03%	3.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.110M	$530.0K	$260.0K
YoY Change	208.33%	103.85%	420.0%
Accrued Expenses	$3.400M	$3.180M	$3.480M
YoY Change	-1.16%	-8.62%	-30.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$5.640M
YoY Change	-100.0%	-100.0%	183.42%
Total Short-Term Liabilities	$4.817M	$3.631M	$9.380M
YoY Change	-53.23%	-61.29%	33.62%
LONG-TERM LIABILITIES
Long-Term Debt	$9.901M	$9.891M	$5.120M
YoY Change	26.45%	93.18%
Other Long-Term Liabilities	$10.00K	$50.00K	$1.610M
YoY Change	-97.83%	-96.89%
Total Long-Term Liabilities	$9.940M	$9.891M	$6.730M
YoY Change	19.9%	46.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.817M	$3.631M	$9.380M
Total Long-Term Liabilities	$9.940M	$9.891M	$6.730M
Total Liabilities	$14.76M	$13.52M	$16.11M
YoY Change	-20.66%	-16.06%	129.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$92.10M	-$84.35M
YoY Change
Common Stock	$142.3M	$141.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.22M	$57.07M	-$1.260M
YoY Change
Total Liabilities & Shareholders Equity	$64.98M	$70.59M	$14.86M
YoY Change	333.48%	375.03%	3.63%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$7.730M	-$7.745M	-$3.581M
YoY Change	87.12%	116.28%	67.89%
Depreciation, Depletion And Amortization	$40.00K	$30.00K	$40.00K
YoY Change	0.0%	-25.0%	-20.0%
Cash From Operating Activities	-$5.650M	-$8.353M	-$4.982M
YoY Change	1.07%	67.66%	-11.35%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$381.0K	$45.00K
YoY Change		746.67%	-325.0%
Acquisitions
YoY Change
Other Investing Activities	-$1.850M	-$22.53M	$3.790M
YoY Change	-78.54%	-694.46%
Cash From Investing Activities	-$1.850M	-$22.91M	$3.747M
YoY Change		-711.42%	-18835.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.00K	$0.00	$2.000K
YoY Change	-99.66%	-100.0%	-99.96%
NET CHANGE
Cash From Operating Activities	-5.650M	-$8.353M	-$4.982M
Cash From Investing Activities	-1.850M	-$22.91M	$3.747M
Cash From Financing Activities	20.00K	$0.00	$2.000K
Net Change In Cash	-7.480M	-$31.26M	-$1.233M
YoY Change	-2177.78%	2435.52%	548.95%
FREE CASH FLOW
Cash From Operating Activities	-$5.650M	-$8.353M	-$4.982M
Capital Expenditures	-$10.00K	$381.0K	$45.00K
Free Cash Flow	-$5.640M	-$8.734M	-$5.027M
YoY Change	0.89%	73.74%	-10.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	140898000	USD
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001427570
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16792147	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	OBALON THERAPEUTICS INC
CY2017Q1	dei	Trading Symbol TradingSymbol	OBLN
CY2016Q4	obln	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	101000	USD
CY2017Q1	obln	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	122000	USD
CY2016Q4	obln	Accrued Legal Current AccruedLegalCurrent	53000	USD
CY2017Q1	obln	Accrued Legal Current AccruedLegalCurrent	159000	USD
CY2016Q1	obln	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	-241000	USD
CY2017Q1	obln	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	21000	USD
CY2017Q1	obln	Nonvested Stock Options Early Exercised NonvestedStockOptionsEarlyExercised	176542	shares
CY2016	obln	Stock Options Early Exercised StockOptionsEarlyExercised	252453	shares
CY2017Q1	obln	Stock Options Early Exercised StockOptionsEarlyExercised	0	shares
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	595000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	823000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1035000	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-25000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	560000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	170000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1084000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1151000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-19000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	141424000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	21000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8447296	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	914575	shares
CY2016Q4	us-gaap	Assets Assets	78778000	USD
CY2017Q1	us-gaap	Assets Assets	70590000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	78061000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	69687000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	2500000	USD
CY2017Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	66458000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	129000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3356000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2123000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72975000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41712000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1233000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-31263000	USD
CY2017Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.1918
CY2017Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	24224	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4767515	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16773205	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16773302	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16773205	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16773302	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3583000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7763000	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	622000	USD
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	823000	USD
CY2017Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10000000	USD
CY2017Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	109000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	121000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	171000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	45000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	66000	USD
CY2016Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	515000	USD
CY2017Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.22
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2497000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1555000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4600000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M18D
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-23000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-13000	USD
CY2017Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	447000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	649000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	174000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	217000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1035000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	50000	USD
CY2016Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	258000	USD
CY2017Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-515000	USD
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1000000	USD
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-942000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	191000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	101000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	14000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-240000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-115000	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-147000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-54000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	132000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	130000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	44000	USD
CY2017Q1	us-gaap	Interest Payable Current InterestPayableCurrent	44000	USD
CY2016Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	5000	USD
CY2017Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	45000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	209000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	360000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	827000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	928000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	379000	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	457000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	239000	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	111000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	14473000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	13522000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78778000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70590000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4592000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3631000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	9891000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9881000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9891000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3747000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22910000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4982000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8353000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3581000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-7745000	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	3891000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	8340000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3444000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7691000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	691000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	100000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	397000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	194000	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	100000	USD
CY2017Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	100000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	621000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	587000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1244000	USD
CY2017Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1004000	USD
CY2016Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	277000	USD
CY2017Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	154000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-18000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1278000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	960000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	381000	USD
CY2016Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2008000	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	25029000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	962000	USD
CY2017Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	805000	USD
CY2016Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	5800000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	2500000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1801000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2054000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	717000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	903000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2512000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2400000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76609000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84354000	USD
CY2016Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1069000	USD
CY2017Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	188956	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12891000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2225684	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2414464	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.00
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4865000	USD
CY2016Q1	us-gaap	Revenues Revenues	1100000	USD
CY2016Q1	us-gaap	Revenues Revenues	1069000	USD
CY2017Q1	us-gaap	Revenues Revenues	1472000	USD
CY2017Q1	us-gaap	Revenues Revenues	1500000	USD
CY2016Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	0	USD
CY2017Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1472000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1379000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5940000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	50000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	463000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5331
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0153
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	79	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	606435	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.67
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11738000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2129264	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.18
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.93
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.76
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.44
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M8D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y3M14D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M21D
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	2500000	USD
CY2017Q1	us-gaap	Short Term Investments ShortTermInvestments	25008000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	97	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	64305000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	57068000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	575855	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16562030	shares
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-005305-index-headers.html	Edgar Link	pending
0001628280-17-005305-index.html	Edgar Link	pending
0001628280-17-005305.txt	Edgar Link	pending
0001628280-17-005305-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
obalon-exhibit311rasdal.htm	Edgar Link	pending
obalon-exhibit312plovanic.htm	Edgar Link	pending
obalon-exhibit32.htm	Edgar Link	pending
obalon-plovanicofferletter.htm	Edgar Link	pending
obln-20170331.xml	Edgar Link	completed
obln-20170331.xsd	Edgar Link	pending
obln-20170331_cal.xml	Edgar Link	unprocessable
obln-20170331_def.xml	Edgar Link	unprocessable
obln-20170331_lab.xml	Edgar Link	unprocessable
obln-20170331_pre.xml	Edgar Link	unprocessable
obln-33117x10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSLS
ReShape Lifesciences Inc. Stock $rsls

2017 Q2 Form 10-Q Financial Statement

#000162828017005305 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS ReShape Lifesciences Inc. Stock $rsls

2017 Q2 Form 10-Q Financial Statement

#000162828017005305 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS
ReShape Lifesciences Inc. Stock $rsls